Bayer adjusted profit gains 15.8% on Monsanto, consumer health

0
46


The Bayer AG logo sits behind silhouetted members of the management board during the company's annual general meeting in Bonn, Germany, May 25, 2018.

Krisztian Bocsi | Bloomberg | Getty Images

The Bayer AG logo sits behind silhouetted members of the management board during the company’s annual general meeting in Bonn, Germany, May 25, 2018.

Bayer’s adjusted core earnings rose 15.8 percent in the fourth quarter, boosted by the addition of U.S. seeds maker Monsanto and as its consumer healthcare business bounced back from earlier declines.

Fourth-quarter adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) rose to 2.07 billion euros, the maker of pharmaceuticals and farming pesticides said on Wednesday, beating the average analyst projection of 2.0 billion euros.

Previously announced write-downs on the value of consumer health brands and one-off charges from the closure of a German hemophilia drug plant led to a quarterly net loss of 3.9 billion euros.

LEAVE A REPLY

Please enter your comment!
Please enter your name here